NASDAQ · Financial Statements

Altimmune, Inc. (ALT) Financial Statements

$2.12 NASDAQ: ALT Market Cap $412.38M

Altimmune, Inc. most recently reported annual revenue of $0, a net loss of $88.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Altimmune, Inc.: Revenue fell from $5.0M in 2016 to $0 in 2025, a change of -100.0% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -215.4% to -230461.0%, a shift of -230245.6 percentage points; the most recent year shows a net loss of $88.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$5.0M$0$10.0M$6.0M$8.0M$4.0M$0$0$0$0
Operating Expenses$16.0M$52.0M$53.0M$27.0M$63.0M$101.0M$88.0M$96.0M$103.0M$95.0M
Operating Profit$-11.0M$-52.0M$-43.0M$-21.0M$-55.0M$-97.0M$-88.0M$-96.0M$-103.0M$-94.0M
Operating Margin-215.4%-125401.2%-414.6%-370.0%-669.5%-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Other Income$0$0$-2.0M$1.0M$11.0M$0$3.0M$7.0M$8.0M$6.0M
Interest$0$0$0$0$0$0$0$0$0$2.0M
Depreciation$0$0$0$0$0$1.0M$0$0$0$0
Profit Before Tax$205.0M$-52.0M$-45.0M$-21.0M$-44.0M$-97.0M$-85.0M$-88.0M$-95.0M$-89.0M
Tax$5.5M$10.8M$13.6M$280,000$-12.4M$0$230,000$0$0$770,000
Net Profit$194.0M$-46.0M$-39.0M$-21.0M$-49.0M$-97.0M$-85.0M$-88.0M$-95.0M$-88.0M
EPS$-49.80$-108.77$-13.98$-1.56$-1.91$-2.35$-1.81$-1.66$-1.34$-1.00
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$23.0M$34.0M$27.0M$27.0M$25.0M$25.0M$22.0M$23.0M$21.0M$29.0M$24.0M$26.0M
Operating Profit$-23.0M$-34.0M$-27.0M$-27.0M$-25.0M$-25.0M$-22.0M$-23.0M$-21.0M$-29.0M$-24.0M$-26.0M
Operating Margin-6226.5%-90873.0%-535880.0%-534900.0%-495340.0%-497320.0%-436300.0%-458440.0%-417180.0%-111126.9%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$1.0M$1.0M$1.0M
Profit Before Tax$-21.0M$-32.0M$-24.0M$-25.0M$-23.0M$-23.0M$-20.0M$-22.0M$-19.0M$-27.0M$-23.0M$-23.0M
Tax$0$0$0$0$0$0$3.4M$0$0$0$0$0
Net Profit$-21.0M$-32.0M$-24.0M$-25.0M$-23.0M$-23.0M$-20.0M$-22.0M$-19.0M$-27.0M$-23.0M$-23.0M
EPS$-0.39$-0.54$-0.34$-0.35$-0.32$-0.33$-0.26$-0.27$-0.21$-0.27$-0.18$-0.12

Over the 10 years reported for Altimmune, Inc., borrowings increased from $1.0M in 2016 to $36.0M in 2025, cash stood at $44.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 18.53 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$225.0M$63.0M$55.0M$54.0M$245.0M$219.0M$207.0M$211.0M$139.0M$280.0M
Current Assets$222.0M$23.0M$39.0M$39.0M$230.0M$204.0M$193.0M$210.0M$137.0M$278.0M
Cash$154.0M$9.0M$34.0M$9.0M$116.0M$190.0M$111.0M$135.0M$37.0M$44.0M
Inventory$0$4.0M$0$0$0$0$0$0$0$0
Receivables$1.0M$10.0M$4.0M$2.0M$12.0M$6.0M$3.0M$5.0M$3.0M$2.0M
Fixed Assets$0$1.0M$1.0M$2.0M$2.0M$1.0M$1.0M$1.0M$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$67.0M$-5.9B$-58.0M$28.0M$100.0M$0$74.0M$63.0M$95.0M$230.0M
Other Assets$19.0M$0$0$0$0$0$0$0$0$0
Total Liabilities$205.0M$14.0M$6.0M$9.0M$19.0M$20.0M$22.0M$17.0M$16.0M$55.0M
Current Liabilities$205.0M$4.0M$5.0M$4.0M$12.0M$18.0M$17.0M$12.0M$10.0M$15.0M
Borrowings$1.0M$0$1.0M$2.0M$2.0M$2.0M$1.0M$1.0M$2.0M$36.0M
Other Liabilities$204.0M$14.0M$6.0M$7.0M$17.0M$18.0M$21.0M$16.0M$14.0M$19.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$19.0M$49.0M$48.0M$46.0M$226.0M$199.0M$185.0M$194.0M$124.0M$225.0M

For Altimmune, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $68.0M; free cash flow was positive in 1 of 10 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$202.0M$-20.0M$-9.0M$-10.0M$-34.0M$-78.0M$-63.0M$-76.0M$-80.0M$-68.0M
Investing Cash Flow$-67.0M$14.0M$-2.0M$-28.0M$-73.0M$75.0M$-74.0M$14.0M$-28.0M$-132.0M
Financing Cash Flow$-1.0M$0$-3.0M$0$41.0M$0$0$0$0$-1.0M
Net Cash Flow$138.0M$9.0M$22.0M$-25.0M$107.0M$74.0M$-79.0M$24.0M$-98.0M$7.0M
Free Cash Flow$201.0M$-20.0M$-10.0M$-10.0M$-35.0M$-91.0M$-63.0M$-76.0M$-80.0M$-68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-5.31
FCF Yield-14.74%
Quick Ratio26.78
Interest Coverage-28.34
Return 1Y-33.80%
Return 3Y-8.09%
Return 5Y-66.01%

Altimmune, Inc. (ALT) financials — frequently asked questions

What is Altimmune, Inc.'s annual revenue?

Altimmune, Inc. (ALT) reported annual revenue of $0 in its most recent fiscal year.

What is Altimmune, Inc.'s net profit?

Altimmune, Inc. (ALT) reported a net loss of $88.0M in its most recent fiscal year.

What is ALT EV/EBITDA?

Altimmune, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -5.31. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
ALT Overview ALT Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.